Vaxcyte, Inc. 4

COO Jim Wassil of Vaxcyte, Inc. exercised 2,250 stock options at $5.35 and sold a total of 2,250 common shares around $53.5–$54.1 on August 3, 2026 under a Rule 10b5-1 plan.

On August 3, 2026, Vaxcyte, Inc. COO Jim Wassil exercised 2,250 stock options at $5.35 per share, acquiring an equal number of common shares, and on the same day sold 861 shares at a weighted-average price of $53.502 and 1,389 shares at a weighted-average price of $54.089 pursuant to a pre-arranged Rule 10b5-1 trading plan. The gross value of the option exercise was approximately $12,038 while the aggregate sale proceeds were roughly $121,500, resulting in a net increase of 0 shares from the option exercise offset by the sales but leaving him with a sizable remaining direct holding. Following these transactions, Wassil directly owned 157,541 shares of Vaxcyte common stock, which, using the prevailing sale prices as a proxy, are worth on the order of $8.4–$8.5 million. The filing also notes that this position includes 781 shares acquired earlier under the company’s Employee Stock Purchase Plan and confirms that the stock option exercised is fully vested and exercisable.

Filing Facts

CIK

1649094

Ticker

PCVX

Form

4

Source Type

fda

Accession

0001813798-26-000015

Alert Tier

6